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Enduring misconceptions about the physical effects of ﬁber in the gut have led to
misunderstandings about the health beneﬁts attributable to insoluble and soluble ﬁber.
This review will focus on isolated functional ﬁbers (eg, ﬁber supplements) whose effects
on clinical outcomes have been readily assessed in well-controlled clinical studies. This
review will also focus on three health beneﬁts (cholesterol lowering, improved glycemic
control, and normalizing stool form [constipation and diarrhea]) for which reproducible
evidence of clinical efﬁcacy has been published. In the small bowel, clinically mean-
ingful health beneﬁts (eg, cholesterol lowering and improved glycemic control) are
highly correlated with the viscosity of soluble ﬁbers: high viscosity ﬁbers (eg, gel-
forming ﬁbers such as b-glucan, psyllium, and raw guar gum) exhibit a signiﬁcant
effect on cholesterol lowering and improved glycemic control, whereas nonviscous
soluble ﬁbers (eg, inulin, fructooligosaccharides, and wheat dextrin) and insoluble ﬁbers
(eg, wheat bran) do not provide these viscosity-dependent health beneﬁts. In the large
bowel, there are only two mechanisms that drive a laxative effect: large/coarse insoluble
ﬁber particles (eg, wheat bran) mechanically irritate the gut mucosa stimulating water
and mucous secretion, and the high water-holding capacity of gel-forming soluble ﬁber
(eg, psyllium) resists dehydration. Both mechanisms require that the ﬁber resist
fermentation and remain relatively intact throughout the large bowel (ie, the ﬁber must
be present in stool), and both mechanisms lead to increased stool water content,
resulting in bulky/soft/easy-to-pass stools. Soluble fermentable ﬁbers (eg, inulin, fruc-
tooligosaccharide, and wheat dextrin) do not provide a laxative effect, and some ﬁbers
can be constipating (eg, wheat dextrin and ﬁne/smooth insoluble wheat bran particles).
When making recommendations for a ﬁber supplement, it is essential to recognize
which ﬁbers possess the physical characteristics required to provide a beneﬁcial health
effect, and which ﬁber supplements are supported by reproducible, rigorous evidence of
one or more clinically meaningful health beneﬁts.
J Acad Nutr Diet. 2017;117:251-264.I
N 2002, THE INSTITUTE OF MEDICINE PUBLISHED A
deﬁnition of total ﬁber that differentiated dietary ﬁber
(ie, nondigestible carbohydrates and lignin that are
intrinsic and intact in plants) from functional ﬁber (ie,
isolated, nondigestible carbohydrates that have been shown
to have beneﬁcial physiologic effects in humans).1 By this
deﬁnition, the isolated nondigestible carbohydrates found in
ﬁber supplements must show clinical evidence of a health
beneﬁt to be considered a functional ﬁber. The term ﬁber
supplement may lead health care professionals and/or con-
sumers to believe that regular consumption will providehealth beneﬁts that may be missing from a low-ﬁber diet. For
many ﬁber supplements, this belief is not supported by
reproducible, well-controlled clinical evidence of a health
beneﬁt. It is therefore important to understand which ﬁber
supplements have clinical evidence of a meaningful health
beneﬁt, and which do not.
Although observational studies have reported health ben-
eﬁts associated with high intakes of dietary ﬁber from whole
foods, such as a reduced risk of developing colorectal cancer,2
enhanced immune function,3 and less weight gain over time,4
the lack of establishing causality is a recognized limitation ofOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 251
Figure. Viscous and gel-forming linear polymers. Drawings
represent viscous linear polymers (top) and gel-forming linear
polymers (bottom).
RESEARCHthese studies. Further, attributing the speciﬁc beneﬁcial ef-
fects to the dietary ﬁber component of whole foods, as
opposed to the effects of other health-promoting constitu-
ents, is a daunting task. This review will focus on the bene-
ﬁcial effects of the isolated functional ﬁbers found in ﬁber
supplements, which are readily assessed for efﬁcacy and
mechanism of action in well-controlled, randomized clinical
trials (RCTs). The review will provide an objective assessment
of the totality of evidence from RCTs on three health beneﬁts
for which reproducible evidence of clinical efﬁcacy have been
published: lowering elevated serum cholesterol concentra-
tions, improving glycemic control, and normalizing stool
form in constipation and diarrhea.
METHODS
A comprehensive literature review was conducted with the
use of the Scopus and PubMed scientiﬁc databases, without
limits to year of publication (latest date included: July 9,
2016). Key search words included: ﬁber, inulin, dextrin,
wheat dextrin, resistant maltodextrin, guar gum, oat, oat
bran, b-glucan, barley, psyllium, ispaghula, polydextrose,
soluble corn ﬁber, methylcellulose, fructooligosaccharide,
galactooligosaccharide, oligofructose, laxation, laxative, con-
stipation, stool, water content, bran, wheat bran, soluble,
insoluble, cholesterol, glycemic, blood glucose, and post-
prandial. Published clinical studies were identiﬁed, and
assessed for study design, study population, and ﬁber dose.
The reference section of each identiﬁed publication was
also searched for any studies that might have been missed
in the database searches.
Professional recommendations are ideally based on
rigorous, reproducible clinical data, so only those studies that
were randomized to treatment, and assessed treatment ef-
fects vs a concurrent (parallel or crossover) control group (eg,
placebo) were considered for inclusion in this review.
Sequential studies that assessed a change from baseline in a
metabolic risk factor were not included in the review because
they do not account for period effects (a placebo treatment
group can also show a signiﬁcant change from baseline).
We also decided to exclude one study because we were
concerned about the results. The study by Dehghan
and colleagues5 assessed oligofructose-enhanced inulin
(10 g/day) in 46 Iranian womenwith type 2 diabetes. Because
the magnitude of the reported results were extreme outliers
(eg, low-density lipoprotein [LDL] cholesterol level decreased
from 116 mg/dL [3.0 mmol/L) to 3797 mg/dL [0.962.51
mmol/L]), far exceeding the effects observed with a high
dose/high-impact statin drug,6 we believed we were justiﬁed
in not including this article in our review.
RESULTS
Misconception #1: All Soluble Fibers Lower Elevated
Serum Cholesterol Levels
Although it is true that some soluble ﬁbers can effectively
lower elevated serum cholesterol concentrations, it is not
true that all soluble ﬁbers have this effect. As will be dis-
cussed in the following paragraphs, only highly viscous sol-
uble ﬁbers (eg, gel-forming ﬁbers such as b-glucan, psyllium,
and raw guar gum) have been shown to exhibit this viscosity-
dependent health beneﬁt. Isolated functional ﬁbers have
unique characteristics based on the way in which the252 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSpolymer sugar chains interact with one another (eg, highly
branched vs straight chains).7 Highly branched, bush-like
polymers with multiple branches at irregular intervals do
not pack in a regular array, have no signiﬁcant effect on
viscosity, and are referred to as nonviscous (eg, inulin, fruc-
tooligosaccharides, and wheat dextrin). In contrast, straight-
chain or linear polymers can pack into a regular array, and
the longer the straight chain, the greater the effect on vis-
cosity (see the Figure). A linear polymer in which the adja-
cent chains form cross-links can form a gel (eg, b-glucan,
psyllium, and raw guar gum) (see the Figure).
It has been hypothesized that soluble, nonviscous,
fermentable ﬁbers (eg, inulin, fructooligosaccharides), also
referred to as prebiotics, can normalize blood lipid concen-
trations via the byproducts of fermentation.1 Although lipid-
lowering effects for inulin and oligofructose have been
observed in rodents, the ﬁber dose administered in these
studies was very high (50 to 200 g/kg body weight per day).8
To put this in perspective, a comparable dose for a 75-kg
person would be 3,750 to 15,000 g (3.7 to 15 kg) of readily
fermented ﬁber per day, several orders of magnitude above a
reasonable/tolerable dose. The 2002 Dietary Reference Intake
(DRI) guidelines for ﬁber suggest that fermentable inulin and
oligofructose could normalize blood lipid concentrations.1 The
DRI authors did acknowledge that the results for this health
effect were mixed, but the studies they cited showed a single
positive effect on one lipid (ie, triacylglycerol) without
acknowledging that the same studies failed to show a signiﬁ-
cant difference for total cholesterol and LDL cholesterol.9-11 A
review of the available published literature yielded 17 ran-
domized, well-controlled clinical studies that assessed the
effects of soluble nonviscous, fermentable ﬁbers on blood lipid
concentrations, and none of these studies showed a signiﬁcant
difference in total and LDL cholesterol compared with the
placebo control (Table 1).9-25 Of these 17 studies, seven were
published before 2002 (1997-2000) and were available for
consideration in the DRI document.9-12,14,16,23 The additional
10 studies were published after 2002 (2003-2013), repre-
senting new information.13,15,17-22,24,25 Of the 16 studies that
assessed the triglyceride-lowering effects of soluble nonvis-
cous fermentable ﬁbers, 13 showed no effect of the ﬁber
compared with the placebo on triglyceride levels. It should be
noted that if one looks across numerous studies, each with
multiple end points assessed for a P value of 0.05, a few of
those end points can show a statistically signiﬁcant differenceFebruary 2017 Volume 117 Number 2
Table 1. Nonviscous fermentable soluble ﬁbers have no effect on lipid metabolism or glycemic control
Reference
Study design, duration
of treatment
Fiber (dose)
[subjects]
Signiﬁcant reduction
in total cholesterol and
low-density lipoprotein
cholesterol vs placebo?
Signiﬁcant
reduction in
triglycerides
vs placebo?
Signiﬁcant
reduction in
postprandial
and/or fasting
blood glucose
vs placebo?
Causey and colleagues12 RCTa, crossover, 3 wk Inulin (20 g/d) [12 hyperlipidemia] No No No
Giacco and colleagues13 RCT, crossover, 2 mo FOSb (10.6 g/d) [30 hyperlipidemia] No No No
Alles and colleagues14 RCT, crossover, 20 d FOS (15 g/d) [20, T2DMc] No No No
Jackson and colleagues9 RCT, parallel, 8 wk Inulin (10 g/d) [54 middle-aged] No Yes No
Letexier and colleagues15 RCT, crossover, 3 wk Inulin (10 g/d) [8 healthy] No Yes No
Pedersen and colleagues10 RCT, crossover, 4 wk Inulin (14 g/d) [64 healthy] No No —
Luo and colleagues11 RCT, crossover, 4 wk FOS (20 g/d) [12 healthy] No No No
Luo and colleagues16 RCT, crossover, 4 wk FOS (20 g/d) [10 T2DM] No No No
Forcheron and Beylot17 RCT, parallel, 6 mo Inulin/FOS mix (10 g/d) [17 healthy] No No No
De Luis and colleagues18 RCT, parallel, 1 mo FOS (10 g/d) [38 obese] No No No
Dewulf and colleagues19 RCT, parallel, 3 mo Inulin/FOS mix (16 g/d) [30 obese] No No No
Parnell and Reimer and
colleagues20
RCT, parallel, 12 wk FOS (21 g/d) [48 obese] No — No
Tovar and colleagues21 RCT, parallel, 3 mo Inulin (10 g/d) [144 obese] No No No
Vulevic and colleagues22 RCT, crossover, 12 wk GOSd (5.5 g/d) [45 MSe] No Yes No
Davidson and colleagues23 RCT, crossover, 6 wk Inulin (18 g/d) [25 hyperlipidemia] No No —
Russo and colleagues24 RCT, crossover, 5 wk Inulin (11 g/d) [22 healthy] No No —
Daubioul and colleagues25 RCT, crossover, 8 wk OFf (16 g/d) [7 NASHg] No No No
aRCT¼randomized controlled trial.
bFOS¼fructooligosaccharide.
cT2DM¼type 2 diabetes mellitus.
dGOS¼galactooligosaccharide.
eMS¼metabolic syndrome.
fOF¼oligofructose.
gNASH¼nonalcoholic steatohepatitis.
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RESEARCHvs placebo by random chance. The few positive outliers must
be viewed in the context of the totality of available well-
controlled clinical evidence. Taken together, the totality of
reproducible well-controlled clinical evidence shows that
nonviscous fermentable ﬁbers have no effect on lipid
metabolism, and debunks the concept that nonviscous
fermentable ﬁbers normalize blood lipid levels (eg, total
cholesterol, LDL cholesterol, and triglycerides) via byproducts
of fermentation.
In contrast to nonviscous ﬁbers, the importance of viscosity
was clearly demonstrated in a well-controlled clinical study
that compared the cholesterol-lowering effectiveness of
several different viscosities of b-glucan, a gel-forming soluble
ﬁber.26 In this double-blind, parallel-design, multicenter
clinical study, 386 subjects were randomly assigned to
receive cereal containing insoluble wheat bran (negative
control) or one of three gel-forming oat bran cereals (3 to 4
g/day b-glucan that was high, medium, or low viscosity).26
The degree of processing (heat and pressure for extrusion)
was used to lower the normally high viscosity of gel-forming
b-glucan. The results showed that cholesterol lowering was
highly correlated with the viscosity of the gel-forming ﬁber:
the high-viscosity gel (low heat and pressure processing)
exhibited signiﬁcant LDL-cholesterol lowering (e5.5%;
P<0.05 vs bran placebo), as did the medium-viscosity gel
(e4.7%; P<0.05), whereas the lower viscosity b-glucan did
not exhibit a signiﬁcant cholesterol-lowering effect.26 A
similar study assessed the cholesterol-lowering effects of raw
oat b-glucan in orange juice (5.0 g/day) vs the same ﬁber
baked into bread (5.9 g/day).27 Only the raw b-glucan
signiﬁcantly decreased LDL cholesterol (e6.7%; P<0.001) vs
insoluble wheat bran (placebo control).27 These data show
the importance of considering not only the speciﬁc ﬁber, but
also the degree of processing for the ﬁnal marketed product.
Note that both nonviscous soluble ﬁbers and insoluble ﬁber
do not provide this viscosity-dependent health beneﬁt, and
can be used as a negative control (ie, placebo).26,28-30
The primary mechanism by which a gel-forming ﬁber
lowers serum cholesterol levels is by trapping and elimi-
nating bile via the stool.31 Bile is produced by the liver, stored
and concentrated in the gall bladder, and released into the
small bowel in response to a meal. Bile facilitates the diges-
tion and absorption of dietary lipid levels, and is normally
recovered in the terminal ileum and recycled, up to several
times within a given meal.7 In contrast to nutrient absorp-
tion, which can occur along the entire length of the small
bowel, the recovery of bile is limited to the terminal ileum,
providing only a brief opportunity for bile reabsorption. A
gel-forming ﬁber becomes more concentrated as water is
reabsorbed along the length of the small bowel, causing it to
become more viscous, trapping bile (interfering with reab-
sorption). The trapped bile is eliminated via the stool.7 The
reduction in the bile acid pool causes hepatocytes to
compensate by stimulating LDL receptor expression/
increasing LDL cholesterol clearance to synthesize more bile
acids (cholesterol is a component of bile) and maintain suf-
ﬁcient bile for digestion. This clearance of LDL cholesterol
from the blood effectively lowers serum LDL cholesterol and
total cholesterol concentrations, without signiﬁcantly
affecting high-density lipoprotein cholesterol concentra-
tion.7,31 Only gel-forming ﬁber supplements (eg, high-
molecular-weight b-glucan, raw guar gum, and psyllium),254 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSconsumed with meals to coincide with bile release, have the
requisite high viscosity to effectively lower elevated serum
cholesterol concentrations.7,26,28,31-33
It is important to note that not all viscous ﬁbers can
effectively lower elevated serum cholesterol concentrations.
A placebo-controlled, randomized, parallel study (105 pa-
tients with hypercholesterolemia) assessed the cholesterol-
lowering effects of psyllium (a natural gel-forming ﬁber) vs
methylcellulose (a semisynthetic viscous soluble ﬁber made
from wood pulp) and polycarbophil (a synthetic polymer).34
The subjects received one of the three treatments three
times a day for 8 weeks. The results showed that LDL
cholesterol concentrations were signiﬁcantly lower with gel-
forming psyllium (8.8%; P¼0.02) vs placebo, but not for
methylcellulose or calcium polycarbophil.34 The effectiveness
of psyllium for lowering elevated serum cholesterol levels has
been assessed in 21 randomized, well-controlled clinical
studies (more than 1,500 subjects) at doses of 6 to 15 g/day
(most studies at 10 g/day), with all studies showing signiﬁ-
cant cholesterol-lowering effects, ranging from e2% to e20%
for total cholesterol, and e6% to e24% for LDL cholesterol, vs
placebo.33-53 The efﬁcacy of psyllium tended to be greatest in
studies assessing patients with a high baseline cholesterol
concentration, and in studies where the diet was not
restricted. Note that the cholesterol-lowering beneﬁt for
psyllium is also additive to the effects of both statin drugs
and bile acid sequestrants.54-59
In summary, cholesterol-lowering efﬁcacy is highly
dependent on the viscosity of the hydrated ﬁber: The higher
the viscosity, the greater the potential effect on lowering
elevated blood cholesterol concentrations. The viscosity of a
gel-forming ﬁber can actually be a better predictor of
cholesterol-lowering efﬁcacy than the quantity of ﬁber
consumed.30 Insoluble ﬁber (eg, wheat bran), low-viscosity
soluble ﬁber (eg, gum Arabic/acacia gum, methylcellulose,
or low-molecular-weight b-glucan) and nonviscous soluble
fermentable ﬁber (eg, inulin, fructooligosaccharides, and
wheat dextrin) supplements do not exhibit a signiﬁcant
cholesterol-lowering beneﬁt at physiologic doses. Note that
b-glucan and psyllium, both gel-forming ﬁbers, are the only
two ﬁbers with a Food and Drug Administration-authorized
health claim to reduce the risk of cardiovascular disease by
lowering serum cholesterol levels.60 Taken together, the to-
tality of clinical evidence debunks the concept that nonvis-
cous fermentable ﬁbers normalize blood lipid levels via
byproducts of fermentation. Only high-viscosity ﬁbers pro-
vide this health effect, so it is important to consider not only
the type of ﬁber to recommend, but also the degree of pro-
cessing (eg, heat/pressure extrusion into cereal shapes) that
may attenuate the efﬁcacy of marketed products.Misconception #2: All Soluble Fibers Improve
Glycemic Control
Although it is true that some soluble ﬁbers improve glycemic
control, it is not true that all soluble ﬁbers have this beneﬁcial
effect. Similar to the effects of high-viscosity ﬁber supple-
ments on elevated serum cholesterol concentrations,
improving glycemic control is a viscosity-dependent phe-
nomenon. The 2002 DRI guidelines for ﬁber suggested that
fermentable inulin and oligofructose could attenuate blood
glucose responses, again citing a few human studies with aFebruary 2017 Volume 117 Number 2
RESEARCHsingle positive end point.1 The 14 randomized, well-
controlled clinical studies listed in Table 1 show that none
of the fructans (ie, inulin, fructooligosaccharide, gal-
actooligosaccharide, and oligofructose) showed evidence of
improved glycemic control vs placebo. Based on the totality
of evidence from 14 randomized, well-controlled, reproduc-
ible clinical studies, it is reasonable to conclude that soluble
nonviscous fermentable ﬁbers do not attenuate blood glucose
responses or improve glycemic control.
In contrast to the above-mentioned nonviscous ﬁbers, it
was demonstrated more than 3 decades ago that the effec-
tiveness of soluble ﬁber on glucose and insulin metabolism is
proportional to the viscosity of the hydrated ﬁber.61 In a
study published in 1978,61 volunteers consumed 50 g liquid
glucose with and without highly viscous raw guar gum. The
high-viscosity (gel-forming) ﬁber exhibited a clinically
meaningful decrease in postprandial blood glucose and in-
sulin concentrations compared with liquid glucose alone. The
beneﬁcial effect on postprandial measures was abolished
when the guar gum was hydrolyzed to a nonviscous form.
After comparing several gelling ﬁbers of different viscosities,
the authors concluded that the reduction in postprandial
blood glucose level was highly correlated with the viscosity
of the hydrated ﬁber (r¼0.926; P<0.01).61 A challenge with
consumption of raw guar gum is that it rapidly forms a tight
gel, rendering it unpalatable when hydrated. In an attempt to
make guar gum more palatable, manufacturers hydrolyze the
guar gum (eg, partially hydrolyzed guar gum), resulting in a
low viscosity/nonviscous product. As discussed above, this
processing renders the guar gum ineffective for viscosity-
dependent health beneﬁts like cholesterol lowering and
improved glycemic control, so it is important to consider
processing when recommending a ﬁber supplement.
Although postprandial glucose studies are a useful tool for
assessing acute glycemic effects, long-term (multimonth)
data from well-controlled intervention clinical studies are
necessary to establish a clinically meaningful health beneﬁt
for improved glycemic control. Several multimonth clinical
studies have demonstrated that consumption of a soluble,
viscous, ﬁber supplement (eg, gel-forming ﬁbers such as
psyllium and guar gum), dosed with meals, can improve
glycemic control (lower fasting blood glucose, insulin, and
glycated hemoglobin levels) in subjects at risk for developing
type 2 diabetes, and patients being treated for type 2 dia-
betes.7,31,38-40,62-64
The primary mechanism for improving glycemic control
with a soluble, viscous ﬁber supplement is by signiﬁcantly
increasing the viscosity of chyme in a dose-dependent
manner.63 The increased viscosity slows interactions of
digestive enzymes and nutrients, which slows the degrada-
tion of complex nutrients into absorbable components, and
slows the absorption of glucose and other nutrients at the
brush border.7,31 Nutrients are normally absorbed early in the
small bowel, but the increase in chyme viscosity and slowing
of nutrient degradation/absorption can lead to increased
delivery of nutrients to the distal ileum, where nutrients are
normally not present or only minimally present. Nutrients
delivered to the distal ileum can stimulate mucosal L-cells to
release glucagon-like peptide-1 into the bloodstream.7
Glucagon-like peptide-1 is a short-lived (approximately
2-minute half-life) peptide that signiﬁcantly decreases
appetite, increases pancreatic beta-cell growth (cells thatFebruary 2017 Volume 117 Number 2produce insulin), improves insulin production and sensitivity,
and decreases glucagon-secretion (a peptide that stimulates
glucose production in the liver). Delivery of lipids, carbohy-
drates, and protein to the distal ileum can also stimulate the
ileal brake phenomenon, which has been deﬁned as “.a
distal to proximal feedback mechanism to control transit of a
meal through the gastrointestinal tract in order to optimize
nutrient digestion and absorption.”65 Slowing gastric
emptying and small bowel transit via the ileal brake has been
shown to reduce both hunger and food intake.65 It is
important to note that although a viscous ﬁber can slow the
absorption of nutrients, it does not reduce total nutrient ab-
sorption.66 Unlike bile, which is only absorbed in a short
segment of the distal ileum, nutrients are absorbed along the
entire 7-m length of the small bowel, providing ample op-
portunity for nutrient absorption to occur.7,31 The ileal brake
phenomenon can effectively slow gastric emptying and small
bowel transit to attenuate the loss of nutrients to the large
bowel.7,31,65
Similar to cholesterol lowering, the long-term glycemic
effects of viscous/gel-forming ﬁber are also proportionate to
baseline glycemic control,67 no signiﬁcant effect in euglyce-
mia,36,43,47 a modest effect in prediabetes/metabolic syn-
drome (eg, e19.8 mg/dL [e1.1 mmol/L] for psyllium 3.5 g two
times per day and e9 mg/dL [e0.5 mmol/L] for guar gum 3.5
g two times per day)38 and the greatest effect in patients
being treated for type 2 diabetes mellitus (eg, psyllium, e35.0
to e89.7 mg/dL [e1.9 mmol/L to e4.98 mmol/L]).39,62,63
Taken together, these studies show that improved glycemic
control is proportionate to the viscosity of a hydrated ﬁber
(eg, gel-forming raw guar gum, high-molecular-weight
b-glucan, and psyllium). Insoluble ﬁber (eg, wheat bran and
cellulose) and soluble nonviscous ﬁbers (eg, inulin, wheat
dextrin, polydextrose, soluble corn ﬁber, and resistant
maltodextrin) do not provide these viscosity-dependent
health beneﬁts at physiologic doses.Misconception #3a: All Fibers Provide a Regularity
Beneﬁt
Regularity can be deﬁned as the regular (eg, daily) elimina-
tion of bulky/soft/easy-to-pass stools. Constipation can be
deﬁned as infrequent (<3 bowel movements [BMs] per week)
elimination of small/hard stools that are difﬁcult to pass.7
Normal BM frequency is considered to be at least three BMs
per week to 3/day.7 Although BM frequency is often used as a
measure of regularity, it should not be the primary measure.
For example, one person may strain to pass a single small,
hard marble-like stool every day (eg, 7 BMs/wk), whereas
another may have a bulky/soft/easy-to-pass stool every other
day (eg, 3 to 4 BMs/wk). In this instance, the person with the
higher BM frequency is constipated, whereas the other is not.
The most important consideration for assessing a clinically
meaningful regularity beneﬁt with increased ﬁber con-
sumption is evidence of a signiﬁcant increase in both stool
output (assessed as grams of stool per day for healthy sub-
jects, can be assessed as grams per week in chronic con-
stipation) and stool water content (%). Stool water content is
highly correlated with stool consistency, and is the mecha-
nism for both a stool softening effect and a stool bulking
effect.7,68 There are two mechanisms by which ﬁber can
provide a signiﬁcant regularity beneﬁt (laxative effect): large/JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 255
RESEARCHcoarse insoluble ﬁber particles (eg, wheat bran) have a
mechanically irritating effect on large bowel mucosa, stimu-
lating secretion of water and mucous, and soluble
gel-forming ﬁber (eg, psyllium) has a high water-holding
capacity that resists dehydration in the large bowel.7,68 For
both mechanisms, ﬁber must resist fermentation to remain
intact and present throughout the length of the large bowel
(must be present in stool; prerequisite #1), and ﬁber must
increase stool water content (prerequisite #2) leading to
bulky/soft stools that are easy to pass.7,31 An appreciation for
the strong correlation between stool water content and stool
consistency can provide insights into why some functional
ﬁbers provide an effective regularity/laxative beneﬁt, why
some do not, and how some functional ﬁbers can actually
have a constipating effect.
Digesta is normally a liquid (90% water) when it arrives in
the cecum, and it is gradually dehydrated along the entire
length of the large bowel, resulting in formed stool (z75%
water content) in the rectum.7,31,68 As discussed above, when
considering the regularity/laxative effects of ﬁber in the large
intestine, the isolated ﬁber must meet two prerequisites to
provide a signiﬁcant beneﬁt. A ﬁber must resist fermentation
to remain relatively intact and present throughout the length
of the large bowel (be present in stool) because transit through
the large bowel normally takes 1 or more days, and the large
bowel is quite efﬁcient at absorbing water along its entire
length. A ﬁber that is readily fermented in the proximal large
bowel cannot signiﬁcantly affect the water content of stool in
the distal bowel 1 or more days later. Exposure of the stool to
the mucosa throughout the remainder of the large bowel,
without the presence of intact ﬁber, would result in signiﬁcant
stool dehydration. A ﬁber must signiﬁcantly increase the
percent water content of stool, which is the primary driver for
both softening stool and increasing stool bulk.68,69 The water
content of stool is inversely proportional to stool viscosity.68,69
As stool water content decreases, stool viscosity increases
exponentially: liquid stool is z90% water content; soft stool
is z77% water; formed stool is z75% water, and hard stool
is 72% water.7,31,68-70 This 18% difference in stool water
content (from 90% to 72%) represents a 240-fold increase in
stool viscosity (from liquid to hard).7,68-70 By increasing stool
water content, an effective ﬁber therapy will keep stools soft/
formed, and signiﬁcantly increase stool bulk, both of which
make stools easy to pass without straining. An ineffective
ﬁber would either have no signiﬁcant effect on stool water
content/stool bulk, or would add to the dry mass of stool,
which would decrease the percentage of stool water content
and result in harder stools. The following sections will discuss
different ﬁber types (eg, insoluble ﬁber, soluble gel-forming
ﬁber, and soluble nonviscous ﬁber) as they relate to a regu-
larity beneﬁt/laxative effect.
Although it is true that some ﬁbers provide a regularity/
laxative beneﬁt, it is not true that all ﬁbers have this effect. As
with normalizing blood lipid levels and attenuating glucose
response, the DRI guidelines cite a few studies that suggest a
laxative effect for inulin, oligofructose, and fructooligo-
saccharides. In theory, fermentable ﬁbers would increase the
mass of bacteria, thereby increasing stool output. In contrast
to this theory, data from well-controlled RCTs show that
fermentable ﬁbers have no effect on stool output or stool
softening. Table 2 summarizes the results from 21 well-
controlled RCTs that assessed the laxative effects (stool256 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSoutput, stool softening, and/or BM frequency) of nonviscous
soluble fermentable ﬁbers.71-87 Of the 15 studies that
assessed stool output, 14 showed no effect of the fermentable
ﬁbers compared with the placebo. One study in 36 healthy
subjects showed that a high dose of polydextrose (20 g/day
for 10 days) resulted in a minimal (2 g stool per gram ﬁber;
2 g/g) but statistically signiﬁcant effect on stool output.83 In
contrast, a similar study in 21 healthy adults, with a higher
dose (21 g/day) of polydextrose for 3 weeks, showed no effect
on stool output.81 In addition, four other studies with more
reasonable doses (4 to 12 g/day) for 3 to 4 weeks also failed to
show a signiﬁcant effect of polydextrose on stool output or
other regularity/laxative outcome measures compared to the
placebo.72,82,86,87 Of the 21 studies that assessed a stool
softening effect, 20 showed no effect of the ﬁber compared
with the placebo (Table 2).
Of the 17 studies that assessed BM frequency, 14 showed no
effect with fermentable ﬁbers. The 3 studies that exhibited a
small increase in BM frequency administered a relatively high
ﬁber dose (inulin 15 g/day, soluble corn ﬁber 20 g/day, and
polydextrose 20 g/day), yet studies with a similar or higher
dose of the same ﬁbers failed to demonstrate this effect
(Table 2). Further, an increase in BM frequency without a
signiﬁcant increase in daily stool output, and a signiﬁcant
stool softening effect, means that each BM produced smaller,
potentially harder stools. As described previously, more
frequent BMs with smaller/harder stools is not a health
beneﬁt. The totality of clinical evidence supports that
fermentable ﬁbers do not provide a laxative effect/regularity
beneﬁt. Further, at least one soluble fermentable ﬁber, wheat
dextrin, has been shown to have a constipating effect.84,85
Two well-controlled crossover clinical studies showed that
10 to 15 g/day wheat dextrin resulted in a decrease in stool
output and a decrease in stool water content (smaller/harder
stools), as well as subjective reports of harder stools by
healthy subjects.84,85 One additional soluble ﬁber, methyl-
cellulose (semisynthetic; chemically treated wood pulp), was
not included in Table 2 because it is viscous and not fer-
mented in the human gut. Methylcellulose has an over-the-
counter indication for regularity, but no well-controlled
clinical studies were identiﬁed to support a laxative effect
in constipation. One study that assessed a change from
baseline in healthy subjects failed to show a dose-response in
stool output across a fourfold increase in the dose of meth-
ylcellulose.88 The totality of clinical evidence debunks the
concept that all ﬁbers provide a regularity beneﬁt.Misconception #3b: Insoluble Fiber has High Water-
Holding Capacity (Holds Water Like a Sponge) that
Provides a Regularity/Laxative Beneﬁt
For insoluble ﬁber, there continues to be a misconception
that the observed increase in stool water content associated
with its laxative effect is due to water-holding capacity.89-91
In reality, insoluble ﬁber has no signiﬁcant interaction with
water and no appreciable water-holding capacity in the large
bowel, yet it can signiﬁcantly increase both stool water
content (soften stools) and stool bulk.92 The question is,
How? The answer: Insoluble particles have a mechanically
irritating effect on the mucosa of the large bowel, stimulating
secretion of water and mucous as a defense mechanism to
protect from abrasion.7,92 Insoluble ﬁber (eg, wheat bran) isFebruary 2017 Volume 117 Number 2
Table 2. Particulars of studies71-87 showing fermentable ﬁbers have no signiﬁcant effect on objective measures of regularity/laxation
Reference
Study design, duration
of treatment Fiber dose (subjects)
Signiﬁcant increase
in stool output
vs placebo?
Signiﬁcant
stool softening
effect vs placebo?
Signiﬁcant bowel
movement frequency
increase vs placebo?
Inulin
Slavin and Feirtag71 RCTa, crossover, 3-wk 20 g/d (12 healthy) No No No
Costabile and colleagues73 RCT, crossover, 3-wk 10 g/d (32 healthy) — No No
Van Dokkum and colleagues74 RCT, crossover, 3-wk 15 g/d (12 healthy) No No —
Ramnani and colleagues75 RCT, parallel, 3-wk 5 g/d (66 healthy) — No No
Kleesen and colleagues76 RCT, parallel, 2-wk 15 g/d (45 healthy) — No No
Waitzburg and colleagues77 RCT, parallel, 3-wk 15 g/d (60 constipated) — — No
Marteau and colleagues78 RCT, parallel, 4-wk 15 g/d (50 constipated) — No No
Dahl and colleagues79 RCT, crossover, 3 wk 13 g/d (15 institutionalized) — — No
Den Hond and colleagues80 RCT, crossover, 1-wk 15 g/d (6 healthy) No No Yesb
Soluble corn ﬁber
Boler and colleagues81 RCT, crossover, 3-wk 21 g/d (21 healthy) No No —
Stewart and colleagues82 RCT, crossover, 2-wk 12 g/d (20 healthy) No No No
Timm and colleagues83 RCT, crossover, 10-d 20 g/d (36 healthy) No No Yesb
Dextrin
Van den Heuvel and colleagues84 RCT, crossover, 1-wk WDc 10 and 15 g/d (20 healthy) No No No
Van den Heuvel and colleagues85 RCT, crossover, 1-wk WD 10 and 15 g/d (20 healthy) No No No
Stewart and colleagues82 RCT, crossover, 2-wk SDd 12 g/d (20 healthy) No No No
Polydextrose
Costabile and colleagues72 RCT, crossover, 3-wk 8 g/d (31 healthy) No No No
Boler and colleagues81 RCT, crossover, 3-wk 21 g/d (21 healthy) No No —
Jie and colleagues86 RCT, parallel, 4-wk 4, 8, and 12 g/d (120 healthy) No No No
Hengst and colleagues87 RCT, parallel, 3-wk 8 g/d (45 healthy) No No —
Timm and colleagues83e RCT, crossover, 10-d 20 g/d (36 healthy) Yes Yes Yes
Resistant starch
Stewart and colleagues82 RCT, crossover, 14-d 12 g/d (20 healthy) No No No
aRCT¼randomized controlled trial.
bAn increase in bowel movement frequency without an increase in stool output and stool water content means each bowel movement produced a smaller, potentially harder stool, which is not a health beneﬁt.
cWD¼wheat dextrin.
dSD¼soluble dextrin.
eA high-dose (20 g/d) outlier study with nonreproducible results. Other studies of polydextrose failed to show an effect, even at a higher dose (Boler and colleagues81).
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RESEARCHpoorly fermented, so it remains relatively intact and present
throughout the large bowel (prerequisite #1).92 The obser-
vation that coarse wheat bran had a greater laxative effect
than ﬁne wheat bran suggested that the insoluble particles
themselves may have a direct effect in the large bowel.93 This
observation led to several studies comparing insoluble wheat
bran to swallowed inert plastic particles (plastic effect) at the
same grams per day dose as the wheat bran.94-96 Note that
plastic particles have no water-holding capacity and are not
fermented by bacteria, so any observed laxative effect would
be purely mechanical in nature.
The studies clearly showed that swallowed plastic particles,
cut to match the size and shape of wheat bran particles
milled to different sizes, exhibited the same laxative effect:
large/coarse particles had a profound laxative effect, whereas
small/smooth particles had no effect.94-96 These studies
conﬁrmed that the laxative effect of insoluble ﬁber was due
to mechanical irritation of the mucosa, causing secretion of
water and mucous, leading to bulky/soft/easy-to-pass stools.
One study assessed ﬁnely ground wheat bran and showed
that it added to the dry mass of stool, effectively lowering the
percent stool water content, which led to harder stools and
reports from healthy subjects that they developed difﬁcult/
uncomfortable BMs during the wheat bran treatment period
(constipating effect).97
In summary, for both coarse wheat bran and coarse plastic
particles, the observed increase in stool output and the stool
softening effect were due to mechanical irritation of the large
bowel mucosa (plastic effect), stimulating secretion of water
and mucous. Large/coarse particles can provide a signiﬁcant
laxative effect/regularity beneﬁt, whereas ﬁne/smooth par-
ticles can have a constipating effect, providing a rationale for
why laxative-effect clinical data for insoluble ﬁber may
appear inconsistent. When considering insoluble ﬁber for a
clinical study or professional recommendation, attention
must be paid to the particle size/coarseness of the ﬁnal
marketed product. Further, the lack of water-holding capacity
and the mucosa irritating effect make insoluble ﬁber a poor
choice for attenuating symptoms in irritable bowel
syndrome.98,99Misconception #3c: All Soluble Fermentable Fibers
Provide a Regularity Beneﬁt/Laxative Effect by
Increasing the Biomass
Although it is true that consumption of some fermentable
ﬁbers can cause increases and decreases in speciﬁc bacteria
(eg, prebiotic effect), it is a misconception that these rela-
tively small opposing changes to a few speciﬁc bacteria
provide a signiﬁcant regularity/laxative beneﬁt. Fibers that
are readily fermented do not remain intact and present
throughout the large bowel (do not meet prerequisite #1)
and have no signiﬁcant water-holding capacity in the large
bowel (do not meet prerequisite #2), so mechanistically
would not be expected to provide a regularity beneﬁt. As
discussed in section 3a, the totality of well-controlled clinical
evidence shows that soluble fermentable ﬁbers have no effect
on stool output (Table 2).
Similarly, many gel-forming soluble ﬁbers (eg, b-glucan,
guar gum, and xanthan gum) are readily fermented in the
large bowel, resulting in the loss of both their gelled nature
and their water-holding capacity.7,92,100,101 At extreme doses258 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS(eg, 87 to 100 g/day), oat bran consumption resulted in a
minimal effect on stool output (<1 g stool per gram ﬁber),
likely because it outpaced the capacity of bacterial fermen-
tation, but stool water content decreased (harder stools) in
healthy subjects, which is inconsistent with a health
beneﬁt.102-104 Taken together, the totality of clinical evidence
shows that soluble fermentable ﬁbers do not signiﬁcantly
increase stool output, and therefore do not provide a regu-
larity beneﬁt/laxative effect. Further, the lack of an effect on
stool output by fermentable ﬁbers debunks the concept that
increasing the biomass provides a regularity beneﬁt.
In contrast to readily fermented soluble ﬁbers, gel-forming
psyllium is not fermented in the human gut,7,92,105 so it re-
mains intact and present throughout the large bowel and
retains its high water-holding capacity, providing bulky/soft
stools that are easy to pass.7,68,69,92 In a randomized, double-
blind, 4-week (2-week baseline and 2-week treatment)
clinical study that assessed the stool softening/laxative
effects of psyllium (5.1 g twice a day) vs docusate (marketed
as a stool softener, 100 mg twice a day) in 170 patients with
chronic idiopathic constipation, the data showed that psyl-
lium was superior to the stool softener for increasing stool
water content (softer stools, P<0.01), stool output (P<0.005),
and BM frequency (P<0.05).69 A more recent randomized,
placebo-controlled study investigated the effects of psyllium
(10.5 g/day for 4 weeks) in 48 patients with chronic con-
stipation.106 The study showed that psyllium treatment
signiﬁcantly (P<0.05) reduced abdominal pain scores (e58%),
reduced colonic transit time (e11 hours), increased BM fre-
quency (threefold increase), and softened hard stools (þ1 on
the Bristol Stool Scale) vs placebo.106
It is important to note that observed increases in stool
output for constipated patients will typically be lower than
those observed for healthy subjects at the same ﬁber dose.
For example, psyllium showed an increase in stool output of 4
to 5 g/g in healthy volunteers, but a smaller increase (1.4 to
3.7 g/g) in patients with chronic idiopathic con-
stipation.69,92,107,108 Many studies that assess the stool effects
of isolated ﬁbers are conducted with healthy subjects. It is
important to note that an observed increase in stool output
with healthy subjects is not necessarily predictive of a regu-
larity beneﬁt/laxative effect in constipation, particularly
when the observed increase in stool output for healthy sub-
jects is minimal (eg, 2 g/g) and is not associated with a
signiﬁcant increase in stool water content (stool-softening
effect). To recommend an effective ﬁber therapy that treats/
prevents constipation (maintains regularity), one must look
for a ﬁber with multiple clinical studies showing reproducible
evidence of a meaningful increase in both stool output (>2
g/g in healthy subjects and >1 g/g in constipated subjects)
and stool water content (softer stools) at a reasonable dose
(eg, 15 g/day) (eg, coarse wheat bran and psyllium).Misconception #3d: If Fiber Provides a Signiﬁcant
Laxative Beneﬁt, Too Much of that Fiber can Cause
Diarrhea
In theory, this may be true for the mechanically irritating
effects of insoluble ﬁber, particularly in patients with irritable
bowel syndrome.92,99,109-111 In contrast, if a gel-forming sol-
uble ﬁber can resist fermentation (prerequisite #1) and retain
its high water-holding capacity throughout the large bowelFebruary 2017 Volume 117 Number 2
Table 3. Clinically demonstrated health beneﬁts associated with common ﬁber supplements
Characteristic
No Water-Holding Capacity Water-Holding Capacity
Insoluble
Wheat bran
Soluble No Viscosity
Viscous
Methylcellulose
Viscous/Gel-Forming
Wheat dextrin Inulin
Partially hydrolyzed
guar gum b-glucan Psyllium
Example All Brana Beneﬁberb Fiber Choicec MiraFiber Citruceld Generic Quaker Oatse Metamucilf
Source Wheat Chemically altered
wheat starch
Chicory root Chemically altered
wood pulp
Guar beans Oats, barley Blonde psyllium
seed husk
Natural? Natural Semisynthetic Natural Semisynthetic Processed (Y viscosity) Natural Natural
Degree of fermentation Poorly
fermented
Readily
fermented
Readily
fermented
Nonfermented Readily
fermented
Readily
fermented
Nonfermented
Cholesterol lowering g þh þ
Improved glycemic control g þh þ
Constipation/stool softener þi j þ
Diarrhea/stool normalizer þ
aKellogg’s.
bNovartis.
cPrestige Brands.
dGSK Group.
eQuaker Oats Company.
fProcter & Gamble.
gRaw guar gum a viscous/gel-forming ﬁber, but partially hydrolyzed guar gum is hydrolyzed to reduce viscosity (eliminate gelling) for improved palatability. A reduction in viscosity (loss of gel-formation) correlates with a reduction in/loss of efﬁcacy.
hTypically marketed in ﬁber bars or cereals, requiring pressure and heat to make the ﬁnal product, potentially reducing viscosity (gel-forming capacity). Efﬁcacy depends on ﬁnal viscosity (gel-forming).
iEfﬁcacy is dependent on particle size/coarseness. Large/coarse particles show efﬁcacy. Fine/smooth particles can be constipating.
jMethylcellulose has an over-the-counter indication for relief of constipation, but there are no well-controlled studies in constipated subjects to support this indication. The American College of Gastroenterology determined that methylcellulose had
insufﬁcient clinical data to recommend it for treatment of chronic constipation.123
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RESEARCH(prerequisite #2), it can provide a dichotomous, stool
normalizing effect to soften hard stool (increase BM fre-
quency) in constipation,68,92 and ﬁrm loose/liquid stool
(decrease BM frequency) in diarrhea.92 Psyllium has been
shown to soften hard stool/reduce symptoms in patients with
chronic constipation,68,69,108 and improve stool form/reduce
symptoms in chronic diarrhea,112,113 lactulose-induced diar-
rhea,114 Crohn’s disease,115 and phenolphthalein-induced
diarrhea.116 Clinical studies have also shown psyllium to be
effective for normalizing stool form and reducing symptoms
in irritable bowel syndrome.99,117,118Misconception #3e: Fiber Exerts a Laxative/
Regularity Beneﬁt by Stimulating Large
Bowel Motility
To understand how ﬁber exerts a laxative effect, it is impor-
tant to understand the motor activity of large bowel, where
z95% of motor events are segmental (mixing) pressure
waves that facilitate the absorption of water and electrolytes,
and the remaining z5% are propagating pressure waves
(peristalsis) that propel contents toward the anus.119-121
Propagating pressure waves occur over a wide range of am-
plitudes and propagating rates, from high amplitude (>100
mm Hg), slowly propagating (1 cm/second), infrequent (6/
day) pressure waves that are lumen-occluding events (propel
all contents), to low amplitude (10 mm Hg), rapidly propa-
gating (10 cm/second), frequent (30/day) pressure waves
that only propel gas.7,119-121 Between these extremes are a
range of medium amplitude/propagating rate pressure waves
that propel lower viscosity substrates, like soft stool and
liquids.7,119
How rapidly a substrate transits the large bowel is a
function of viscosity. Gas, the lowest viscosity present in the
large bowel, is easily propelled by all propagating pressure
waves, but primarily by the small/frequent/fast waves that
act like a squeegee to propel intestinal gas rapidly past other
luminal contents (gurgling sound).7,93,119 Gas can traverse the
entire length of the large bowel in <30 minutes (z14 ﬂatu-
lence episodes per day).7,93,119 Liquid stool is propelled by all
but the small/frequent/fast gas waves, resulting in rapid
transit through the large bowel (z1 to 2 hours) and the
potential for frequent BMs (eg, diarrhea).7,92,119 Formed stool
is only propelled by high amplitude, infrequent, slow moving
pressure waves, which is why solid contents may require
days to transit the large bowel (z1 BM per day).7,92,119-121 If
stool becomes very small and hard, it may no longer be
effectively propelled by normal pressure waves, and may
require intervention for evacuation (eg, enema).
An effective ﬁber for laxation does not alter large bowel
motility,122 but instead exerts a regularity beneﬁt by altering
the viscosity of stool.7,68,69,92 With constipation, hard stools
would only be propelled by a few of the highest amplitude
contractions (or none at all, requiring intervention). A stool
softening effect would decrease stool viscosity, making more
of the existing motor events propulsive, increasing both
colonic transit rate and the frequency of bulky/soft/easy-to-
pass stools, thereby relieving symptoms of constipation.7,92
With diarrhea, a stool normalizing/ﬁrming effect would in-
crease the viscosity of stools, making fewer of the existing
motor events propulsive, slowing transit and decreasing BM
frequency.7,92 An effective ﬁber can alter the viscosity of stool,260 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSthereby altering transit rate, but has no signiﬁcant effect on
motility in the large bowel.
CONCLUSIONS
There remains much misinformation in the literature about
the physical effects of ﬁber in the gut. In the small bowel,
ﬁber-related health beneﬁts are dependent on the viscosity of
soluble ﬁbers. High viscosity ﬁbers (eg, gel-forming b-glucan,
psyllium, and raw guar gum) can have a signiﬁcant beneﬁcial
effect on both cholesterol and glycemic control. In contrast,
low viscosity/nonviscous ﬁbers (eg, low-molecular-weight
b-glucan, methylcellulose, inulin, wheat dextrin) and insol-
uble ﬁber (eg, wheat bran and cellulose) have no signiﬁcant
effect on cholesterol concentrations or glycemic control, and
can be used as a placebo. In the large bowel, there are two
mechanisms that drive a regularity/laxative beneﬁt: insoluble
ﬁber mechanically irritates the gut mucosa to stimulate mu-
cous/water secretion, and soluble gel-forming ﬁber that re-
tains a high-water holding capacity that resists dehydration.
To exert a regularity beneﬁt or laxative effect, a ﬁber must
resist fermentation to remain intact and present throughout
the large bowel (be present in stool), and signiﬁcantly in-
crease stool water content. The increase in stool water con-
tent provides bulky/soft/easy-to-pass stools. The plastic effect
of insoluble ﬁber (eg, wheat bran) is dependent on particle
size/coarseness: large/coarse particles have a signiﬁcant
laxative effect; small/smooth particles can have a consti-
pating effect (add only to the dry mass of stool, decreasing
percent water content/hardening stools). The high water-
holding capacity of a nonfermented gel-forming ﬁber (eg,
psyllium) can provide a dichotomous stool normalizing effect;
that is, soften hard stool in constipation and ﬁrm-up loose/
liquid stools in diarrhea, and normalizing stool form in pa-
tients with irritable bowel syndrome. In contrast, the lack of
water-holding capacity for ﬁne insoluble ﬁber (eg, ﬁne wheat
bran) and fermentable soluble ﬁber (eg, wheat dextrin) can
lead to a constipating effect, resulting in a decrease in stool
water content/harder stools. It is therefore essential to
recognize which ﬁbers possess speciﬁc health-promoting
properties, and which ﬁber supplements have consistent,
rigorous evidence of clinically meaningful health beneﬁts at
the doses commonly available in the market place (Table 3).
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